At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylva
CONNECT WITH SUNOVION
Latest Sponsored Posts
Epilepsy Blog Relay: Improving Adherence Requires a Team Approach
Medication “adherence is a crucial part of the journey toward seizure freedom, but for many people with epilepsy, taking their medications on schedule can be very difficult,” said Lucretia Long, APRN-CNP, Ohio State University Wexner Medical Center
This post is part of the Epilepsy Blog Relay™. Follow along all month! For people with epilepsy, uncontrolled seizures (seizures that continue even while you’re on medication)1 can … Read More
DYK? SUDEP is the most common disease-related cause of death in people with epilepsy. By having early conversations and educating patients and families on #SUDEP, we can work with them on the modifiable risk factors (AEDs adherence and adverse events). Read more on the connection between patient education and seizure freedom.